<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">

    <!-- Bootstrap CSS -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-1BmE4kWBq78iYhFldvKuhfTAU6auU8tT94WrHftjDbrCEXSU1oBoqyl2QvZ6jIW3" crossorigin="anonymous">

    <style type="text/css">
      table {
        font-size: small;
      }
      a {
        color: grey;
      }
      a:link {
        text-decoration: none;
      }
      a:hover {
        text-decoration: underline;
      }
      p {
        text-align: justify;
      }
      th {white-space: nowrap;}
      td:nth-child(2)  {white-space: nowrap;}

      /* styling buttons */
      .show-more-btn {
        margin-bottom: 15px;
        cursor: pointer;
        color: #0095e5;
        white-space: nowrap;
        transition: color 300ms ease-in-out;
        border: 0;
        font-size: small;
        background: transparent;
      }
      .show-more-btn:hover {
        color: red;
      }
      .hidden {
        display: none;
      }
    </style>
    <script src="https://cdn.jsdelivr.net/gh/tomik23/show-more@1.1.2/dist/js/showMore.min.js"></script>

    <script type="text/javascript">
      document.addEventListener('DOMContentLoaded', function () {
        // text, table, list, elelemnts
        new ShowMore('.element', {
          onMoreLess: (type, object) => {
            // type = less/more and full object
            console.log(type, object);
          },
        });
      });
    </script>

    <title>Brayniac</title>
  </head>
  <body>
    <div class="container justify-content-center mt-5">
      <div class="col-xxl-8 col-xl-10 col-md-12 mx-auto">
        <div class="row border-bottom mb-4 pb-4">
          <h1 class="mb-5">EndPts</h1>
          <p>
            Brayniac read 100 webpages. This content is about 379 pages long.
          </p>
          <p>
            Brayniac generated a list of keywords on the left and corresponding blurbs on the right. The keywords are ranked by importance. The most important keyword appears at the top. As you scroll down, the keyword importance decreases.
          </p>
          <p>
            The blurb include an actual usage of the keyword from the webpages. It also provides a breakdown of which posts and how many times the keyword appeared in those posts.
          </p>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Alector</h3></div>
          <div class="col-9">
            <p>Alector presents PhII data on lead dementia drug; Chinese oncology biotech nets modest Series</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Eisai</h3></div>
          <div class="col-9">
            <p>LOG IN         Haruo Naito, Eisai CEO (Eisai via LinkedIn)          March 15, 2022 07:15 AM EDT</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Blackstone</h3></div>
          <div class="col-9">
            <p>Rooting for a come-from-behind win, Blackstone infuses $330M into Sanofi's CD38 development plan      Amber Tong   Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Seagen</h3></div>
          <div class="col-9">
            <p>Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen's latest ADC      Max Gelman  Editor      Nicole DeFeudis  Editor      Eight and a half months since its last OK for Xywav, Jazz Pharmaceuticals has won priority review for a new indication with the drug.   The FDA granted the expedited inspection Monday morning, Jazz announced , as the biotech looks to expand Xywav into adult idiopathic hypersomnia patients.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>11 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>AstraZeneca</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                David Fredrickson, AstraZeneca          January 29, 2021 09:53 AM EST</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>12 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>9 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>CMO</h3></div>
          <div class="col-9">
            <p>A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO      Alex Hoffman  Assistant Editor       Kathy Wong  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>15 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>12 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Aduhelm</h3></div>
          <div class="col-9">
            <p>Pharma   Eisai finds an exit from Aduhelm, with small royalties if it ever nabs coverage      Zachary Brennan  Senior Editor       With less than a month to go to the final national coverage determination from CMS, Biogen’s Japanese partner Eisai is essentially cutting its losses on their FDA-approved Alzheimer’s drug.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Exelixis</h3></div>
          <div class="col-9">
            <p>Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero      John Carroll  Editor & Founder      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>9 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Enhertu</h3></div>
          <div class="col-9">
            <p>Another day, another win for Enhertu.   The antibody-drug conjugate AstraZeneca promised up-to $7 billion to partner on</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Seattle Genetics</h3></div>
          <div class="col-9">
            <p>Seven years in the making, Seattle Genetics picks up early option on Genmab's ADC effort      Shehla Shakoor  Managing Director       Clay Siegall  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>10 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Daiichi</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Sunao Manabe, Daiichi Sankyo CEO          October 29, 2021 10:14 AM EDT   R&D   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>9 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Roche</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Roche/Genentech CMO Levi Garraway          December 14, 2021 09:00 AM EST  R&D   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Viatris</h3></div>
          <div class="col-9">
            <p>Pharma Law   Kansas court preliminarily approves Viatris' $264M EpiPen settlement       Nicole DeFeudis  Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Jason Mast</h3></div>
          <div class="col-9">
            <p>Jason Mast  Editor       Amber Tong  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Pfizer</h3></div>
          <div class="col-9">
            <p>A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO      Alex Hoffman  Assistant Editor       Kathy Wong  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>11 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Passage Bio</h3></div>
          <div class="col-9">
            <p>R&D   Roiled by senior-level exits, Jim Wilson’s Passage Bio retrenches, chopping back on staff as it extends cash runway      John Carroll  Editor & Founder       A little more than 3 years after Penn’s Jim Wilson and the late Tachi Yamada heralded the launch of their gene therapy upstart Passage Bio with a bevy of marquee VCs diving in, the biotech is hunkering down for a reorganization.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>CD38</h3></div>
          <div class="col-9">
            <p>Rooting for a come-from-behind win, Blackstone infuses $330M into Sanofi's CD38 development plan      Amber Tong   Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Sarclisa</h3></div>
          <div class="col-9">
            <p>Sanofi is getting a little bit of help to expand its Sarclisa franchise, with Blackstone Life Sciences putting down close to $330 million (€300 million) to fund clinical trials and related costs for a subcutaneous formulation of the drug.   In exchange, Blackstone earns the right to garner royalties on future sales.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ADC Therapeutics</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                ADC Therapeutics CEO Chris Martin (L) and Overland COO/ CBO Ed Zhang          </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Nicole DeFeudis</h3></div>
          <div class="col-9">
            <p>Promising better linker tech to ADC field, Araris has 'very, very ambitious' plans for the clinic      Nicole DeFeudis  Editor       A couple months after raising CHF 2.5 million ($2.76 million) in initial seed funding, one-year-old Araris Biotech is topping off the round with another CHF 12.7 million ($14 million).  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Brigham</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>PhII</h3></div>
          <div class="col-9">
            <p>Treovir has sights set on PhII for pediatric glioblastoma candidate   Treovir is hurrying its glioblastoma candidate into Phase II after a Phase I trial showed the treatment more than doubled the typical survival rate in children with high-grade glioma, the company said on Monday.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Harvard</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Robert Langer</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>MIT</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Mersana</h3></div>
          <div class="col-9">
            <p>, Mersana abandons lead drug      Natalie Grover   Reporter      Mersana Therapeutics’ rocky road in developing its lead drug has culminated in the abandonment of the experimental cancer treatment, days after its high-profile partner Takeda decided to walk away from their deal.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>13 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Genmab</h3></div>
          <div class="col-9">
            <p>FDA hands accelerated nod to Seagen, Genmab's solo ADC in cervical cancer, but combo studies look even more promising       Kyle Blankenship      Biopharma’s resident antibody-drug conjugate expert</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Acepodia</h3></div>
          <div class="col-9">
            <p>Sonny Hsiao (Acepodia)           March 16, 2021 08:00 AM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>11 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Padcev</h3></div>
          <div class="col-9">
            <p>R&D Pharma   Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout      Paul Schloesser  Associate Editor       Astellas and Seagen’s</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Hsiao</h3></div>
          <div class="col-9">
            <p>Sonny Hsiao (Acepodia)           March 16, 2021 08:00 AM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>CMS</h3></div>
          <div class="col-9">
            <p>With less than a month to go to the final national coverage determination from CMS, Biogen’s Japanese partner Eisai is essentially cutting its losses on their FDA-approved Alzheimer’s drug.   The two companies on Wednesday unveiled a reworked partnership for their controversial Alzheimer’s drug Aduhelm, which won a contentious accelerated approval last summer, limped onto the market and now may only be covered in clinical trials if the draft CMS decision gets finalized as is on April 11.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Kadcyla</h3></div>
          <div class="col-9">
            <p>China's ADC market open as Kadcyla scores its first breast cancer OK in the country      Amber Tong  Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Merck</h3></div>
          <div class="col-9">
            <p>Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa      John Carroll  Editor & Founder       While Gilead was crossing the last t’s and dotting the last i’s on their $21 billion deal to buy Immunomedics and their ADC for triple negative breast cancer, Merck was doing the same for a two-pronged, $4.5 billion pact with Seattle Genetics covering another ADC with the same disease target in mind.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>10 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Natalie Grover</h3></div>
          <div class="col-9">
            <p>Natalie Grover  Reporter       Days after Roche secured accelerated approval for its antibody-drug conjugate, Lausanne, Switzerland-based ADC Therapeutics has clinched another $76 million to its already hefty $200 million round of financing unveiled in 2017.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>SVP</h3></div>
          <div class="col-9">
            <p>Ingrid Simms (SVP and principal accounting officer) held the same title at VelosBio and from 2013-20 was the VP of finance for Alder BioPharmaceuticals . Paul Pearson (chief of development) was executive director of preclinical drug metabolism during his years at Merck Research Laboratories , and later became Amgen’s global head of pharmacokinetics and drug metabolism.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>VP</h3></div>
          <div class="col-9">
            <p>Google and Facebook journey takes him to Daphne Koller ’s crew at insitro as VP of product, putting him in charge of enhancing the user experience for its machine-learning apparatus. Besides his years as Google’s director of project management (helping build the Google App Engine) and as Facebook’s VP of search & profile, he’s familiar with the biotech landscape as a technology fellow and a member of the scientific advisory board at Denali , which released less-than-satisfying Hunter syndrome data in July.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Eli Lilly's</h3></div>
          <div class="col-9">
            <p>With Eli Lilly's backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party      Kyle Blankenship      With an industrywide pipeline quickly gathering steam, the Chinese oncology market has become a red-hot market for Western investors as well as Big Pharma partners looking for the next big thing. One way to get there is to get in early, and now Eli Lilly’s Asian investment arm is staking its claim with a team of Seagen veterans.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Daiichi Sankyo</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Sunao Manabe, Daiichi Sankyo CEO          October 29, 2021 10:14 AM EDT   R&D   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ImmunoGen</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Mark Enyedy, ImmunoGen CEO          November 30, 2021 10:36 AM EST  R&D FDA+   ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval      Nicole DeFeudis  Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>EMA</h3></div>
          <div class="col-9">
            <p>Five drugs, including two Novartis therapies, win EMA endorsement      Natalie Grover  Reporter       As is custom, an EMA panel on Friday issued its weekly recommendations on marketing applications submitted by drug developers.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>13 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Polivy</h3></div>
          <div class="col-9">
            <p>Roche's antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma      Kyle Blankenship      Breakthroughs in drug development have begun to unlock the potential of antibody-drug conjugates, therapies designed to better target proteins on tumor cells. Genentech’s Polivy has become an early winner in blood cancer, and now the drugmaker is revealing promising results in getting into patients even sooner.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>12 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Sterling</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Kevin Cook, Sterling Pharma Solutions CEO          March 2, 2022 01:31 PM EST</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Synaffix</h3></div>
          <div class="col-9">
            <p>Chinese player joins a growing group of biotechs buying into Synaffix's ADC linker tech      Amber Tong  Senior Editor       In developing any antibody-drug conjugate, the linker — the hyphen between the antigen-binding antibody and the cancer-killing drug — is of utmost importance.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Kyle Blankenship</h3></div>
          <div class="col-9">
            <p>A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors      Kyle Blankenship       Czech biotech Sotio will pay $29.5 million upfront and in near-term milestones with a potential $1.03 billion in downstream biobucks to license five antibody-drug conjugate programs from LegoChem Biosciences, the partners announced Tuesday.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Gilead</h3></div>
          <div class="col-9">
            <p>Gilead's Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients      Kyle Blankenship       With AstraZeneca and Daiichi sniffing at its trail, Gilead has worked hard to hold an advantage for ADC Trodelvy in particularly hard-to-treat breast cancer patients.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Jim Wilson</h3></div>
          <div class="col-9">
            <p>→ Passage Bio, the Pennsylvania-based gene therapy developer co-founded by Jim Wilson, has appointed  Maxine Gowen as its new chairwoman of the board of directors. The CEO of TamuroBio and former Trevena CEO has been a member of the board since February, and was brought on as chairwoman following former chairman Tachi Yamada ’s death in August .  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Jim Wilson’s</h3></div>
          <div class="col-9">
            <p>R&D   Roiled by senior-level exits, Jim Wilson’s Passage Bio retrenches, chopping back on staff as it extends cash runway      John Carroll  Editor & Founder       A little more than 3 years after Penn’s Jim Wilson and the late Tachi Yamada heralded the launch of their gene therapy upstart Passage Bio with a bevy of marquee VCs diving in, the biotech is hunkering down for a reorganization.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Penn</h3></div>
          <div class="col-9">
            <p>A little more than 3 years after Penn’s Jim Wilson and the late Tachi Yamada heralded the launch of their gene therapy upstart Passage Bio with a bevy of marquee VCs diving in, the biotech is hunkering down for a reorganization. And it comes with the exit of its R&D chief just days after one of the investors on its board quit after registering a sharp disagreement over their plans.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Takeda</h3></div>
          <div class="col-9">
            <p>EST  R&D   Deserted by Takeda , Mersana abandons lead drug      Natalie Grover  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Martin</h3></div>
          <div class="col-9">
            <p>Chris Martin was one of the original board members at ADC back in 2011 when the biotech was launched. Almost exactly three years ago he helped arrange the sale of the UK’s Spirogen — where he was CEO — to AstraZeneca in a $440 million deal, which the pharma giant paired with a $20 million investment in ADC.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ITM</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Steffen Schuster, ITM CEO          April 22, 2021 10:46 AM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>11 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Chris Martin</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Chris Martin, ADC Therapeutics CEO          August 26, 2021 09:27 AM EDT   Deals   ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Astellas</h3></div>
          <div class="col-9">
            <p>Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech      Arsalan Arif  Publisher & Founder      Wataru Uchida, Astellas  A decade ago Agensys’ antibody work looked so appealing that Astellas happily paid $387 million in cash for it, reserving $150 million more in milestones. Today, though, the Japanese pharma company says it is shutting down the operation in Santa Monica, CA and moving on from antibody-drug conjugations, laying off all of the 220 staffers — unless they can land another job in the company.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>BioNova</h3></div>
          <div class="col-9">
            <p>Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal       Paul Schloesser  Associate Editor      Regulus Therapeutics just finished dosing in IND-enabling toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>10 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>SXSW</h3></div>
          <div class="col-9">
            <p>Pfizer’s CEO talks pandemic pressure at SXSW; Exact Sciences teams with Katie Couric for screening       Beth Snyder Bulik  Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Exact Sciences</h3></div>
          <div class="col-9">
            <p>Pfizer’s CEO talks pandemic pressure at SXSW; Exact Sciences teams with Katie Couric for screening       Beth Snyder Bulik  Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Katie Couric</h3></div>
          <div class="col-9">
            <p>Pfizer’s CEO talks pandemic pressure at SXSW; Exact Sciences teams with Katie Couric for screening       Beth Snyder Bulik  Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>TNBC</h3></div>
          <div class="col-9">
            <p>06:45 AM EDT  R&D   AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it's adding more heat under Gilead's Trodelvy      Kyle Blankenship      After the approval of their partnered anti-HER2 antibody-drug conjugate earlier this year, AstraZeneca and Daiichi Sankyo are riding high on the promise of their blooming partnership. Now a second ADC is showing promise in hard-to-treat breast cancer, and the companies have their eyes set on their only approved competitor in the space.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>drugmaker</h3></div>
          <div class="col-9">
            <p>Genentech’s Polivy has become an early winner in blood cancer, and now the drugmaker is revealing promising results in getting into patients even sooner.   A combination of Roche’s Polivy, an ADC targeting the CD79b protein on tumor cells, with Rituxan and the chemotherapy regimen R-CHOP cut the risk of disease progression or death over Rituxan-chemo alone by 27% in patients with first-line diffuse large B cell lymphoma, according to late-breaking data presented Tuesday at #ASH21.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Trodelvy</h3></div>
          <div class="col-9">
            <p>Gilead's Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients      Kyle Blankenship       With AstraZeneca and Daiichi sniffing at its trail, Gilead has worked hard to hold an advantage for ADC Trodelvy in particularly hard-to-treat breast cancer patients.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Keytruda</h3></div>
          <div class="col-9">
            <p>TV will compete with Merck’s Keytruda in second-line cervical cancer, but that competition may quickly turn into collaboration with new combo data showing stronger response rates. The FDA also granted Keytruda an accelerated approval in 2018, based on data showing a 14% response rate — pretty abysmal results but a sign of promise in a big unmet clinical need.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>9 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>FDA</h3></div>
          <div class="col-9">
            <p>FDA+     Financing    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>12 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>10 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>10 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>10 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>LinkedIn</h3></div>
          <div class="col-9">
            <p>John Carroll on LinkedIn        Jason Mast   Editor    </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Iksuda</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Dave Simpson, Iksuda          June 7, 2021 09:13 AM EDT</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>9 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Sutro</h3></div>
          <div class="col-9">
            <p>Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal       Paul Schloesser  Associate Editor      Regulus Therapeutics just finished dosing in IND-enabling toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>9 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ORR</h3></div>
          <div class="col-9">
            <p>It’s early days, but the data stack up well in terms of ORR against Gilead and immunomedics’ Trodelvy, the first TROP2-targeted ADC approved for TNBC in April. AstraZeneca opted in June to shell out $1 billion upfront for co-development rights to datopotamab, a follow-up on its winning partnership with Daiichi on anti-HER2 drug Enhertu.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Pyxis</h3></div>
          <div class="col-9">
            <p>, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs       Amber Tong  Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Biogen</h3></div>
          <div class="col-9">
            <p>“I’ve Been Everywhere” with stints at Amgen, Allergan and Biogen under his belt — just led R&D for a year at Acadia Pharmaceuticals after he was in charge of global neurology clinical development at Eli Lilly. Beals sped into Autobahn in January 2020 as SVP of translational medicine, and earlier he was CMO at Abide Therapeutics , which Lundbeck  bought to boost a scuffling pipeline in the spring of 2019.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Amber Tong</h3></div>
          <div class="col-9">
            <p>Amber Tong  Senior Editor       Lara Sullivan knows how empowering it can be for a biotech to bring in experimental drugs from Pfizer’s shelves.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Genentech</h3></div>
          <div class="col-9">
            <p>Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb      Amber Tong  Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>AXL</h3></div>
          <div class="col-9">
            <p>In their previous work, the NKI researchers — led by Daniel Peeper — have discovered these resistant melanomas start producing another protein called AXL. The fact that this protein often sits on the outside of a tumor cell makes them prime targets for the next generation of melanoma drugs.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>9 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>NK</h3></div>
          <div class="col-9">
            <p>Taiwan's Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells       Max Gelman  Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ADC</h3></div>
          <div class="col-9">
            <p>Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca      John Carroll  Editor & Founder       Just days after Gilead and its new subsidiary Kite won a groundbreaking FDA approval for their CAR-T therapy Yescarta for B-cell lymphomas, Lausanne, Switzerland-based ADC Therapeutics is rolling out a jaw-dropping $200 million mega-round to gamble — in part — on a next-gen antibody-drug conjugate that the backers feel can compete just fine with the personalized cell therapy.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>10 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Amgen</h3></div>
          <div class="col-9">
            <p>From 2009-13, Hall was a medical director at Amgen before becoming an executive medical director at Ardea Biosciences .   Ingrid Simms  →</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>J&J</h3></div>
          <div class="col-9">
            <p>Other companies like Seagen have become leaders in ADC development, with 8 ADCs in their pipeline, while others like J&J laid some sizeable recent bets on ADCs moving forward.    J&J bets $40M cash on biotech's ADC tech and its battle-tested CEO — with biobucks adding to $1B   ADCs work by combining the selectivity of an antibody or antibody fragment with the potency of a small molecule, according to the FDA.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Darzalex</h3></div>
          <div class="col-9">
            <p>Genmab is looking to develop its own pipeline as it looks to build on the success of Darzalex , partnered with J&J. And now the company plans to switch focus to other experimental drugs in the pipeline.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Novo Nordisk</h3></div>
          <div class="col-9">
            <p>Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup      Max Gelman  Editor      John Carroll   Editor & Founder      Pfizer has out-licensed a pair of antibody-drug conjugates to Cambridge, MA-based Pyxis Oncology.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Dermavant</h3></div>
          <div class="col-9">
            <p>Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back      Amber Tong  Senior Editor       Raise money when you can, not when you must —</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Bioscience & Technology Business Center</h3></div>
          <div class="col-9">
            <p>Pfizer’s CEO talks pandemic pressure at SXSW; Exact Sciences teams with Katie Couric for screening     Merck suffers rare Keytruda setback as the blockbuster fails a PhIII prostate cancer test with Lynparza     Genome editing products: FDA recommends at least 15 years of follow-up after clinical trials     Roiled by senior-level exits, Jim Wilson’s Passage Bio retrenches, chopping back on staff as it extends cash runway                 Bioscience & Technology Business Center The University of Kansas Lawrence, Kansas          Latest   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Paul Hudson</h3></div>
          <div class="col-9">
            <p>Paul Hudson, Sanofi CEO (Sipa via AP Images)          March 15, 2022 07:36 AM EDT   R&D   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Sipa</h3></div>
          <div class="col-9">
            <p>Paul Hudson, Sanofi CEO (Sipa via AP Images)          March 15, 2022 07:36 AM EDT   R&D   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>07:36 AM EDT</h3></div>
          <div class="col-9">
            <p>Paul Hudson, Sanofi CEO (Sipa via AP Images)          March 15, 2022 07:36 AM EDT   R&D   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Blackstone Life Sciences</h3></div>
          <div class="col-9">
            <p>Sanofi is getting a little bit of help to expand its Sarclisa franchise, with Blackstone Life Sciences putting down close to $330 million (€300 million) to fund clinical trials and related costs for a subcutaneous formulation of the drug.   In exchange, Blackstone earns the right to garner royalties on future sales.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>anti-CD38</h3></div>
          <div class="col-9">
            <p>While Sanofi had placed high hopes on Sarclisa as a bellwether for its oncology pipeline, the anti-CD38 therapy had struggled on uptake, as it was first approved shortly before the WHO declared a global pandemic in 2020, limiting patient access. The French drugmaker also faces a formidable incumbent in J&J’s Darzalex, which hits the same target.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>WHO</h3></div>
          <div class="col-9">
            <p>While Sanofi had placed high hopes on Sarclisa as a bellwether for its oncology pipeline, the anti-CD38 therapy had struggled on uptake, as it was first approved shortly before the WHO declared a global pandemic in 2020, limiting patient access. The French drugmaker also faces a formidable incumbent in J&J’s Darzalex, which hits the same target.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Lynparza     </h3></div>
          <div class="col-9">
            <p>Merck suffers rare Keytruda setback as the blockbuster fails a PhIII prostate cancer test with Lynparza      Max Gelman  Editor       Merck’s cancer drug Keytruda has become one of the best-selling medicines on the planet thanks to a rigorous clinical development program that’s racked up win after win.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Cami</h3></div>
          <div class="col-9">
            <p>The move clears the way for an anticipated 2021 readout from their second pivotal study, a Phase II trial testing their experimental antibody drug conjugate camidanlumab tesirine, or Cami, in Hodgkin’s lymphoma.   Jay Feingold  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>LegoChem</h3></div>
          <div class="col-9">
            <p>A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors      Kyle Blankenship       Czech biotech Sotio will pay $29.5 million upfront and in near-term milestones with a potential $1.03 billion in downstream biobucks to license five antibody-drug conjugate programs from LegoChem Biosciences, the partners announced Tuesday.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>8 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>UP   LOG</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                        February 3, 2022 10:53 AM</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>01:54</h3></div>
          <div class="col-9">
            <p>LOG IN              March 15, 2022 01:54 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>DLBCL</h3></div>
          <div class="col-9">
            <p>ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment      John Carroll  Editor & Founder       The FDA won’t be waiting around for the PDUFA date for its latest OK on the cancer front.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Clay Siegall</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Clay Siegall (Credit: Life Science Washington via YouTube)          </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Women’s Hospital</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>01:21</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Traverso</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Giovanni Traverso</h3></div>
          <div class="col-9">
            <p>Read More         Giovanni Traverso (L), Harvard’s Brigham and Women’s Hospital and Robert Langer, MIT          March 15, 2022 01:21 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Traverso, Langer                 Bioscience & Technology Business Center</h3></div>
          <div class="col-9">
            <p>Cytiva opens doors at Cardiff site as part of $1.5B global expansion     Novo Nordisk ‘thinking big’ in renewed collaboration with high-profile scientists Traverso, Langer                 Bioscience & Technology Business Center The University of Kansas Lawrence, Kansas          Latest   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>John Carroll</h3></div>
          <div class="col-9">
            <p>an ADC development program after the data fail to impress      John Carroll  Editor & Founder       Genmab $GMAB has opted to ax one of its antibody-drug conjugates after watching it flop in the clinic.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Overland</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                ADC Therapeutics CEO Chris Martin (L) and Overland COO/ CBO Ed Zhang          </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Plexxikon</h3></div>
          <div class="col-9">
            <p>Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development      Max Gelman  Editor       Daiichi Sankyo is saying goodbye to one of its longtime subsidiaries.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Centessa</h3></div>
          <div class="col-9">
            <p>AstraZeneca's Enhertu gets BTD for breast cancer; Centessa nabs $300M loan       Paul Schloesser  Associate Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Yang</h3></div>
          <div class="col-9">
            <p>Editor      Acepodia chairman and co-founder Patrick Yang called cancer “the longest war America (has) ever fought.” So when he met Sonny Hsiao in 2016 and saw his “clever, very simple, elegant” approach to battling tumor cells, he was all in.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>7 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>RayzeBio</h3></div>
          <div class="col-9">
            <p>Ken Song (RayzeBio)          October 14, 2020 08:00 AM EDT   Financing Startups   Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals      Amber Tong  Senior Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Lynparza</h3></div>
          <div class="col-9">
            <p>Merck suffers rare Keytruda setback as the blockbuster fails a PhIII prostate cancer test with Lynparza      Max Gelman  Editor       Merck’s cancer drug Keytruda has become one of the best-selling medicines on the planet thanks to a rigorous clinical development program that’s racked up win after win.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>GSK</h3></div>
          <div class="col-9">
            <p>Back in June, GSK paid Alector $700 million to kickstart an alliance for rights to two drugs targeting a range of neurological diseases.   The next month, Alector showed via early data that one of the drugs, antibody AL001 for a genetic and rapidly progressing form of dementia, brought levels of progranulin back to near-normal levels after six months in nine patients.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>02:00 PM</h3></div>
          <div class="col-9">
            <p>LOG IN                 March 15, 2022 02:00 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Bristol Myers Squibb</h3></div>
          <div class="col-9">
            <p>Novartis, Bristol Myers Squibb bet yes on MPM's platform take      Amber Tong  Senior Editor       Brian Goodman, Patrick Baeuerle and Todd Foley weren’t exactly looking to start a radiopharmaceuticals company.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>10:52 AM EDT</h3></div>
          <div class="col-9">
            <p>10:52 AM EDT  News Briefing    Alector presents PhII data on lead dementia drug;</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>AL001</h3></div>
          <div class="col-9">
            <p>The next month, Alector showed via early data that one of the drugs, antibody AL001 for a genetic and rapidly progressing form of dementia, brought levels of progranulin back to near-normal levels after six months in nine patients. Seven stayed at near-normal after a year.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>progranulin</h3></div>
          <div class="col-9">
            <p>The next month, Alector showed via early data that one of the drugs, antibody AL001 for a genetic and rapidly progressing form of dementia, brought levels of progranulin back to near-normal levels after six months in nine patients. Seven stayed at near-normal after a year.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>The University of Kansas Lawrence</h3></div>
          <div class="col-9">
            <p>The University of Kansas Lawrence, Kansas          Latest    All News  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>09:52</h3></div>
          <div class="col-9">
            <p>09:52 AM EDT  Cell/Gene Tx FDA+   Genome editing products</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Intellia</h3></div>
          <div class="col-9">
            <p>As Intellia recently unveiled its latest promising data around one in a series of potentially game-changing gene therapies, the FDA on Tuesday sought to further encourage the field with new draft guidance on what should be submitted in a clinical trial application and what potentially concerning safety issues to track for these genome editing products.   The agency is upfront about the risks of genome editing, as bluebird bio and others have been hit with clinical holds.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Haruo Naito</h3></div>
          <div class="col-9">
            <p>LOG IN         Haruo Naito, Eisai CEO (Eisai via LinkedIn)          March 15, 2022 07:15 AM EDT</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>07:15</h3></div>
          <div class="col-9">
            <p>LOG IN         Haruo Naito, Eisai CEO (Eisai via LinkedIn)          March 15, 2022 07:15 AM EDT</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Jay Feingold</h3></div>
          <div class="col-9">
            <p>A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO      Alex Hoffman  Assistant Editor       Kathy Wong  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>CBO</h3></div>
          <div class="col-9">
            <p>Smith, the CBO at Verseau since 2019, is a seven-year Celgene alum who has been a CBO before at Cleave Biosciences and led corporate development at Ideaya . PMV added $53 million to its coffers in a Series D from August 2020 to continue its focus on mutant p53 proteins, an especially tough nut to crack against cancer.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>MA</h3></div>
          <div class="col-9">
            <p>Based in Woburn, MA, ReForm Biologics focuses on what they describe as “gentler medicines” for children and the elderly.   Lauren Sabella  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Araris</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Philipp Spycher, Araris CEO          October 22, 2020 04:36 AM EDT  Financing   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Byondis</h3></div>
          <div class="col-9">
            <p>Byondis’ ADC, combining Herceptin with the experimental drug duocarmazine, reached its goal of a statistically significant improvement of progression-free survival over physician’s choice, the biotech said early Tuesday. None of the data were revealed in the topline results, but Byondis noted it plans to submit its pitch to the FDA by the end of the year.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ADCendo</h3></div>
          <div class="col-9">
            <p>ADCendo CEO          April 29, 2021 03:00 AM EDT Updated 04:48 PM  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ICER</h3></div>
          <div class="col-9">
            <p>Max Gelman  ICER launches pilot program to update past assessments using real-world data   ICER is revisiting its 2018 assessments of three prophylactic treatments for hereditary angioedema (HAE) using real-world evidence collected through a partnership with health care tech company Aetion.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Spero</h3></div>
          <div class="col-9">
            <p>A rare antibiotic win for prominently-backed Spero      John Carroll  Editor & Founder       Jason Mast  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Agensys</h3></div>
          <div class="col-9">
            <p>Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech      Arsalan Arif  Publisher & Founder      Wataru Uchida, Astellas  A decade ago Agensys’ antibody work looked so appealing that Astellas happily paid $387 million in cash for it, reserving $150 million more in milestones. Today, though, the Japanese pharma company says it is shutting down the operation in Santa Monica, CA and moving on from antibody-drug conjugations, laying off all of the 220 staffers — unless they can land another job in the company.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>MPM</h3></div>
          <div class="col-9">
            <p>LOG IN                Matthew Roden, Aktis Oncology CEO (MPM Capital)          March 18, 2021 07:07 AM EDT Updated 07:37 AM  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Sotio</h3></div>
          <div class="col-9">
            <p>Czech biotech Sotio will pay $29.5 million upfront and in near-term milestones with a potential $1.03 billion in downstream biobucks to license five antibody-drug conjugate programs from LegoChem Biosciences, the partners announced Tuesday.   Details on the collaboration are slim, but Sotio did say the programs would target distinct antigens in solid tumors.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Immunovant</h3></div>
          <div class="col-9">
            <p>A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO      Alex Hoffman  Assistant Editor       Kathy Wong  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Coherus</h3></div>
          <div class="col-9">
            <p>hands Coherus back a few dollars   Here’s an unusual way to spend cash from a collaboration announcement: handing it back to your collaborator.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Pierre Fabre</h3></div>
          <div class="col-9">
            <p>— Zachary Brennan   Atara and Pierre Fabre join forces for tab-cel commercialization worth up to $365M upfront  Atara Biotherapeutics and Pierre Fabre agreed to an exclusive commercialization agreement for tabelecleucel, or tab-cel in Europe, Middle East, Africa, and other select markets for Epstein-Barr virus (EBV)-positive cancers, according to a statement released today .   Atara will receive $45 million upfront as part of the agreement and up to approximately $320 million in additional milestones, plus royalties.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>NASH</h3></div>
          <div class="col-9">
            <p>Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup      Max Gelman  Editor      John Carroll   Editor & Founder      Pfizer has out-licensed a pair of antibody-drug conjugates to Cambridge, MA-based Pyxis Oncology.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>6 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Cytiva</h3></div>
          <div class="col-9">
            <p>Pharma Manufacturing   Cytiva opens doors at Cardiff site as part of $1.5B global expansion      Josh Sullivan  Associate Editor       In a September interview with Endpoints News, Cytiva CMO Conor McKechnie said that the company was focusing on in-region, for-region manufacturing as the biopharma world felt the impact of supply woes that affected the entire world.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>IND</h3></div>
          <div class="col-9">
            <p>The new round of funding will allow Iksuda to put that candidate into Phase I human trials as well as steer two other candidates — IKS04 and IKS012 — toward IND filing.   The biotech is taking aim specifically at patients with hard-to-treat tumors or those at high risk of relapse, Iksuda said.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Celgene</h3></div>
          <div class="col-9">
            <p>Before making his way to ADC in early 2020, Camardo spent 10 years as an exec at Celgene , where he was SVP of global medical affairs and corporate medical operations, then SVP of Celgene Global Health before the Bristol Myers Squibb deal closed. The Chris Martin -led ADC has expanded its reach into China with its joint venture Overland ADCT BioPharma , which named Eric Koo as its CEO in April.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Bristol Myers</h3></div>
          <div class="col-9">
            <p>Before making his way to ADC in early 2020, Camardo spent 10 years as an exec at Celgene , where he was SVP of global medical affairs and corporate medical operations, then SVP of Celgene Global Health before the Bristol Myers Squibb deal closed. The Chris Martin -led ADC has expanded its reach into China with its joint venture Overland ADCT BioPharma , which named Eric Koo as its CEO in April.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Tachi Yamada</h3></div>
          <div class="col-9">
            <p>→ Jim Wilson ‘s new startup iECURE , which came from his work with Tachi Yamada , has reeled in  Brian Di Donato to its board of directors. Di Donato is currently CFO and head of strategy at Immunocore .</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Pharma   Government</h3></div>
          <div class="col-9">
            <p>Pharma   Government watchdog questions Eli Lilly's campaign contributions       Nicole DeFeudis  Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Capitol</h3></div>
          <div class="col-9">
            <p>A government watchdog group issued a letter to Eli Lilly questioning the company’s campaign contributions to lawmakers who have downplayed or voted against the investigation of last year’s attack on the Capitol.   In response to the Jan. 6 insurrection last year, Lilly’s political action committee, LillyPAC, decided to pause contributions to Republicans who voted against the certification of the 2020 election results.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>01:25 PM EDT</h3></div>
          <div class="col-9">
            <p>More              March 15, 2022 01:25 PM EDT   Pharma Law   Kansas court preliminarily approves Viatris' $264M EpiPen settlement      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>EpiPens</h3></div>
          <div class="col-9">
            <p>A federal court has signed off on a settlement that will see Viatris pay $264 million to resolve claims that it conspired with Pfizer to “monopolize the market” for life-saving EpiPens.   Kansas Judge Daniel Crabtree preliminarily agreed to the settlement on Friday, paving the way for a final approval that won’t come until at least the second half of the year.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Daniel Crabtree</h3></div>
          <div class="col-9">
            <p>Kansas Judge Daniel Crabtree preliminarily agreed to the settlement on Friday, paving the way for a final approval that won’t come until at least the second half of the year. A fairness hearing will take place on July 6, according to court documents.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Lawrence</h3></div>
          <div class="col-9">
            <p>The University of Kansas Lawrence, Kansas          Latest    All News  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Herceptin</h3></div>
          <div class="col-9">
            <p>’s breast cancer franchises has been working on an antibody drug conjugate involving Herceptin. On Tuesday, the Dutch biotech revealed the program had met its primary endpoint in a Phase III study, and they say they’re ready to make a deal.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>PFS</h3></div>
          <div class="col-9">
            <p>Median progression-free survival for Enhertu as determined by a blinded independent review committee had not been reached at 15.5- and 13.9-month check-ins, the partners said, compared with a median PFS of 6.8 months for Kadcyla, otherwise known as T-DM1. But on a secondary endpoint determining PFS by investigator review, Enhertu posted a jaw-dropping three-fold increase over Kadcyla at 25.1 months versus 7.2 months, respectively.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Lausanne</h3></div>
          <div class="col-9">
            <p>Just days after Gilead and its new subsidiary Kite won a groundbreaking FDA approval for their CAR-T therapy Yescarta for B-cell lymphomas, Lausanne, Switzerland-based ADC Therapeutics is rolling out a jaw-dropping $200 million mega-round to gamble — in part — on a next-gen antibody-drug conjugate that the backers feel can compete just fine with the personalized cell therapy.   The latest round brings ADC’s total venture take to $455 million, positioning them for a pair of Phase II studies that potentially could put them in line for an accelerated approval — particularly if they come close to matching the original proof-of-concept data that was posted last June.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Global Forum</h3></div>
          <div class="col-9">
            <p>Jim Wilson (WuXi Global Forum at JPM20)           March 15, 2022 09:12 AM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>09:12 AM EDT</h3></div>
          <div class="col-9">
            <p>March 15, 2022 09:12 AM EDT   R&D   Roiled by senior-level exits, Jim Wilson’s Passage Bio retrenches, chopping back on staff as it extends cash runway      John Carroll  Editor & Founder      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>GM1 gangliosidosis</h3></div>
          <div class="col-9">
            <p>Passage put out word today that it’s chopping 13% of its workforce and circling the wagons around 3 key programs — for GM1 gangliosidosis, Krabbe disease and frontotemporal dementia — which will give it enough cash on hand to get to Q2 2024. The statement didn’t say just how many staffers are being cut, but Passage — closely aligned with Wilson’s Gene Therapy Program at Penn, which has provided rights to a portfolio of products — noted in its last 10-K that it had 133 full time employees, in addition to independent contractors.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Krabbe</h3></div>
          <div class="col-9">
            <p>Passage put out word today that it’s chopping 13% of its workforce and circling the wagons around 3 key programs — for GM1 gangliosidosis, Krabbe disease and frontotemporal dementia — which will give it enough cash on hand to get to Q2 2024. The statement didn’t say just how many staffers are being cut, but Passage — closely aligned with Wilson’s Gene Therapy Program at Penn, which has provided rights to a portfolio of products — noted in its last 10-K that it had 133 full time employees, in addition to independent contractors.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Wilson’s Gene Therapy Program</h3></div>
          <div class="col-9">
            <p>The statement didn’t say just how many staffers are being cut, but Passage — closely aligned with Wilson’s Gene Therapy Program at Penn, which has provided rights to a portfolio of products — noted in its last 10-K that it had 133 full time employees, in addition to independent contractors.    Read</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Zynlonta</h3></div>
          <div class="col-9">
            <p>Kyle Blankenship      ADC Therapeutics will receive $225 million in cash and an additional $100 million in near-term milestones as part of a royalty sale with HealthCare Royalty for its lead antibody-drug conjugate Zynlonta and investigational CD25 candidate camidanlumab tesirine (Cami), the companies said Thursday.   The deal snares HealthCare Royalty a 7% royalty on worldwide net sales and licensing for both drugs, which can be expanded up to 10%.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>UP   </h3></div>
          <div class="col-9">
            <p>SIGN UP    LOG</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>biotech</h3></div>
          <div class="col-9">
            <p>Deals   J&J bets $40M cash on biotech's ADC tech and its battle-tested CEO — with biobucks adding to $1B      Amber Tong  Senior Editor      Trying to see if it can find new uses for a suite of antibodies its Janssen subsidiary has developed, J&J has tapped Mersana Therapeutics for an antibody-drug conjugate discovery pact.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adcs-in-the-pipeline-fda-spells-out-clinical-pharmacology-musts-for-sponsors/">ADCs in the pipeline: FDA spells out clinical pharmacology musts for sponsors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Spirogen</h3></div>
          <div class="col-9">
            <p>In 2013, he engineered the sale of UK’s Spirogen — where he was CEO — to AstraZeneca in a $440 million deal, which the British drugmaker paired with a $20 million investment in ADC. ADC and Spirogen also share the pyrrolobenzodiazepine-based warhead technology.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>API</h3></div>
          <div class="col-9">
            <p>Pharma Manufacturing   Sterling builds up its API capacity with big buy of Novartis campus in Ireland      Josh Sullivan   Associate Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>RemeGen</h3></div>
          <div class="col-9">
            <p>LOG IN                Jianmin Fang, RemeGen CEO (RemeGen)          August 9, 2021 10:55 AM EDT  Deals China   ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Kathy Wong</h3></div>
          <div class="col-9">
            <p>Kathy Wong   Assistant Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Debiopharm</h3></div>
          <div class="col-9">
            <p>FDA pushes back Ascendis' PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC      Max Gelman  Editor      Josh Sullivan   Associate Editor      Danish biotech Ascendis Biopharma has been working on a treatment for pediatric growth hormone deficiency, but the FDA says they’re going to have to wait a little bit longer before they can make their approval decision.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Novo</h3></div>
          <div class="col-9">
            <p>News Briefing   ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study       John Carroll  Editor & Founder      Natalie Grover  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Lu</h3></div>
          <div class="col-9">
            <p>Regulators granted Lu-PSMA-617 breakthrough therapy designation Wednesday, Novartis announced, roughly three months after the candidate read out positive Phase III results in metastatic castration-resistant prostate cancer.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Kyle Blankenship      </h3></div>
          <div class="col-9">
            <p>Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail      Kyle Blankenship       Driven by a series of wins for its antibody-drug conjugate pipeline, Daiichi Sankyo has earned a reputation as an ADC expert with a successful partnership with AstraZeneca under its belt.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Elands</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Jack Elands, Emergence Therapeutics CEO          December 7, 2021 10:20 AM EST Updated 10:43 AM  Financing   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Domainex</h3></div>
          <div class="col-9">
            <p>MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson's program      Josh Sullivan  Associate Editor       Synaffix and MacroGenics have signed a deal to codevelop and commercialize a clinical platform for antibody-drug conjugates to fight cancer.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Spycher</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Philipp Spycher, Araris CEO          October 22, 2020 04:36 AM EDT  Financing   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Qiagen</h3></div>
          <div class="col-9">
            <p>ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world's new favorite biotech       John Carroll  Editor & Founder      Jason Mast  Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Ascendis</h3></div>
          <div class="col-9">
            <p>FDA pushes back Ascendis' PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC      Max Gelman  Editor      Josh Sullivan   Associate Editor      Danish biotech Ascendis Biopharma has been working on a treatment for pediatric growth hormone deficiency, but the FDA says they’re going to have to wait a little bit longer before they can make their approval decision.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Dynavax</h3></div>
          <div class="col-9">
            <p>— Paul Schloesser  Dynavax partners with DoD on recombinant plague vaccine  California-based Dynavax and the US Department of Defense signed an agreement for $22 million over the next 2.5 years to develop a recombinant vaccine against the plague, according to a Dynavax announcement today.   The DoD will develop the vaccine using the agency’s rF1V vaccine and its own adjuvant solution.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Schuster</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Steffen Schuster, ITM CEO          April 22, 2021 10:46 AM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Ringaskiddy</h3></div>
          <div class="col-9">
            <p>The site is in Ringaskiddy, roughly 30 minutes from Cork, Ireland, and right now manufactures APIs in three different buildings on the campus, and has the capacity to scale-up operations and space for R&D. The deal will include a supply agreement between Sterling and Novartis.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Regulus</h3></div>
          <div class="col-9">
            <p>Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal       Paul Schloesser  Associate Editor      Regulus Therapeutics just finished dosing in IND-enabling toxicity studies for its second-generation autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS8429.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Bolt</h3></div>
          <div class="col-9">
            <p>SIGN UP   LOG IN                Randy Schatzman, Bolt CEO (Bolt Biotherapeutics)          July 1, 2020 09:07 AM EDT Updated 03:50 PM  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>5 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>12:25 PM</h3></div>
          <div class="col-9">
            <p>More                 March 15, 2022 12:25 PM EDT  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Beth Snyder Bulik</h3></div>
          <div class="col-9">
            <p>Beth Snyder Bulik  Senior Editor       Pfizer CEO Albert Bourla talked at the annual South by Southwest music, tech and culture festival about the pressure and politicization of the Covid-19 pandemic.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Albert Bourla</h3></div>
          <div class="col-9">
            <p>Pfizer CEO Albert Bourla talked at the annual South by Southwest music, tech and culture festival about the pressure and politicization of the Covid-19 pandemic. He discussed the pressure to create a vaccine with “disappointments every day,” and the eventual politics that came into play in adoption.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Bourla</h3></div>
          <div class="col-9">
            <p>Pfizer CEO Albert Bourla talked at the annual South by Southwest music, tech and culture festival about the pressure and politicization of the Covid-19 pandemic. He discussed the pressure to create a vaccine with “disappointments every day,” and the eventual politics that came into play in adoption.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Austin American</h3></div>
          <div class="col-9">
            <p>“The election polarized it and that was wrong,” Bourla said, according to an Austin American-Statesman  report . He added that there are some people who will never get vaccinated for that reason.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-hands-accelerated-nod-to-seagen-genmabs-solo-adc-in-cervical-cancer-but-combo-studies-look-even-more-promising/">FDA hands accelerated nod to Seagen, Genmab’s solo ADC in cervical cancer, but combo studies look even more promising – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/">ADC Therapeutics nabs its first approval as FDA offers a quick OK for its DLBCL cancer treatment – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-lifts-partial-hold-on-adc-clearing-way-for-a-2021-readout-and-two-potential-near-term-approvals/">FDA lifts partial hold on ADC, clearing way for a 2021 readout and two potential near-term approvals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-big-adc-partner-pledges-to-pour-13-6b-into-cancer-rd-over-next-5-years-and-enhertu-looms-large/">AstraZeneca’s big ADC partner pledges to pour $13.6B into cancer R&D over next 5 years — and Enhertu looms large – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chinese-player-joins-a-growing-group-of-biotechs-buying-into-synaffixs-adc-linker-tech/">Chinese player joins a growing group of biotechs buying into Synaffix’s ADC linker tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astellas-shutters-agensys-and-shrugs-off-a-387m-plus-investment-moving-away-from-adc-tech/">Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-gambles-175m-on-a-triple-pronged-armed-antibody-pact-with-immunogen/">Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/roche-cracks-chinas-adc-market-open-as-kadcyla-scores-its-first-breast-cancer-ok-in-the-country/">Roche cracks China’s ADC market open as Kadcyla scores its first breast cancer OK in the country – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-dustup-between-seagen-and-daiichi-sankyo-nears-the-finish-line-could-it-affect-a-lucrative-astrazeneca-collab/">Seagen and Daiichi are duking it out over the linkers used in some blockbuster drug plays. Could that affect a high-dollar AstraZeneca collaboration? – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ESMO</h3></div>
          <div class="col-9">
            <p>The team brought some positive topline data for their lead candidate, ACE1702, to this year’s ESMO, showing the drug was well-tolerated in eight patients with advanced HER2 tumors who received lower doses. One patient even achieved a confirmed partial response — not earth-shattering, but a positive sign.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>CD20</h3></div>
          <div class="col-9">
            <p>In lymphoma, CD19 and CD20 have cemented themselves as the most prolific targets among cancer drugs, but Roche has looked to partner up Polivy alongside Rituxan, itself a CD20 monoclonal antibody, among other team-ups.   Those combo studies include combining Polivy with Genentech’s in-house bispecific antibodies mosunetuzumab and glofitamab, both of which target CD20.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Big Pharma</h3></div>
          <div class="col-9">
            <p>With Eli Lilly's backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party      Kyle Blankenship      With an industrywide pipeline quickly gathering steam, the Chinese oncology market has become a red-hot market for Western investors as well as Big Pharma partners looking for the next big thing. One way to get there is to get in early, and now Eli Lilly’s Asian investment arm is staking its claim with a team of Seagen veterans.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Daiichi Sankyo’s</h3></div>
          <div class="col-9">
            <p>R&D   AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches      Natalie Grover  Reporter       Buoyed by the performance of its oncology drugs, in March AstraZeneca chief Pascal Soriot bet big to partner with Daiichi Sankyo on its experimental breast cancer drug, with $1.35 billion upfront in a deal worth up to roughly $7 billion .</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>New Jersey</h3></div>
          <div class="col-9">
            <p>→ As Tubridy gets started at Verseau, Tim Smith walks away — writing a new chapter as SVP, head of corporate development at New Jersey p53-focused biotech PMV Pharmaceuticals , chaired by Rich Heyman . Smith, the CBO at Verseau since 2019, is a seven-year Celgene alum who has been a CBO before at Cleave Biosciences and led corporate development at Ideaya .</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>CHMP</h3></div>
          <div class="col-9">
            <p>09:06 AM EDT  News Briefing   CHMP recommends OK for Alnylam's patisiran; Amgen scraps a BCMA ADC      John Carroll  Editor & Founder      → Alnylam  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/five-drugs-including-two-novartis-therapies-win-ema-endorsement/">Five drugs, including two Novartis therapies, win EMA endorsement – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Hong Kong</h3></div>
          <div class="col-9">
            <p>— John Carroll  Antengene goes public in Hong Kong   Antengene, the Hong Kong-based oncology company long backed by Celgene, has gone public in an oversubscribed offering worth roughly $340 million.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/drugmakers-cut-prices-on-average-by-more-than-60-to-get-on-chinas-2022-ndrl-list-report/">Drugmakers cut prices on average by more than 60% to get on China’s 2022 NDRL list — report – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>II</h3></div>
          <div class="col-9">
            <p>The drugmaker’s most advanced candidate is a IL-15 superagonist, dubbed SOT101, that is currently in Phase II testing. The company has a slate of cancer meds set to enter the clinic within the next 12 months, it said in a release.     </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Cambridge</h3></div>
          <div class="col-9">
            <p>Meanwhile, in mid-March, Pfizer inked a deal with Cambridge, MA-based Pyxis Oncology. Pfizer received up-front payment, milestones and some equity in Pyxis, while Pyxis gained rights to Pfizer’s ADC platform.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-backed-mersana-joins-the-biotech-ipo-queue-with-a-75m-offering-and-ambitious-plans-for-adc-tech/">Takeda-backed Mersana joins the biotech IPO queue with a $75M offering and ambitious plans for ADC tech – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>HER2-positive</h3></div>
          <div class="col-9">
            <p>HER2-positive breast cancer patients who had previously undergone treatment with a Herceptin-chemo combo.   Median progression-free survival for Enhertu as determined by a blinded independent review committee had not been reached at 15.5- and 13.9-month check-ins, the partners said, compared with a median PFS of 6.8 months for Kadcyla, otherwise known as T-DM1.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-nabs-speedy-review-as-7b-adc-races-to-blockbuster-status/">AstraZeneca nabs breakthrough status, as $7B ADC races to blockbuster status – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Switzerland</h3></div>
          <div class="col-9">
            <p>From Lausanne, Switzerland, Martin noted he’s been communicating with Boston-based Zhang, Seattle-based Mu and the team in China via “hundreds of Zoom calls and Teams calls” as well as photos.   It helped that he’s met the founders as well as the broader Hillhouse team, he said.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eyeing-an-ipo-adc-therapeutics-fuels-crucial-cancer-trials-with-a-200m-mega-round-backed-by-astrazeneca/">Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Pharma Manufacturing   Cytiva</h3></div>
          <div class="col-9">
            <p>Pharma Manufacturing   Cytiva opens doors at Cardiff site as part of $1.5B global expansion      Josh Sullivan  Associate Editor       In a September interview with Endpoints News, Cytiva CMO Conor McKechnie said that the company was focusing on in-region, for-region manufacturing as the biopharma world felt the impact of supply woes that affected the entire world.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-sells-off-royalty-share-for-lead-antibody-drug-conjugate-in-325m-deal/">ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-czech-biotech-bets-big-on-rising-adc-player-legochem-as-part-of-licensing-pact-aimed-at-solid-tumors/">A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/ash-roches-antibody-drug-conjugate-polivy-added-to-chemo-antibody-combo-boosts-survival-in-early-stage-lymphoma/">ASH: Roche’s antibody-drug conjugate Polivy added to chemo-antibody combo boosts survival in early-stage lymphoma – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-scraps-early-stage-adc-program-in-gastrointestinal-tumors-after-first-phase-fail/">Daiichi Sankyo scraps early-stage ADC program in gastrointestinal tumors after first phase fail – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-a-new-european-biotech-make-an-adc-better-than-padcev-investors-are-putting-up-almost-100m-to-find-out/">Can a new European biotech make an ADC better than Padcev? Investors are putting up almost $100M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jj-bets-40m-cash-on-biotechs-adc-tech-and-its-battle-tested-ceo-with-biobucks-adding-to-1b/">J&J bets $40M cash on biotech’s ADC tech and its battle-tested CEO — with biobucks adding to $1B – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-beefs-up-monster-200m-round-with-another-76m-haul/">ADC Therapeutics beefs up monster $200M round with fresh $76M haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-has-raised-550m-plus-in-its-quest-for-their-first-bla-and-heres-why-thats-important/">ADC Therapeutics has raised $550M-plus in its quest for their first BLA — and here’s why that’s important – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-with-pfizers-adc-platform-pyxis-scores-152m-round-to-shoot-for-the-clinic-while-taking-its-time-on-i-o-programs/">Armed with Pfizer’s ADC platform, Pyxis scores $152M round to shoot for the clinic while taking its time on I/O programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-experts-at-seagen-find-a-2-6b-her2-gem-in-china-that-they-think-can-go-where-enhertu-kadcyla-cant/">ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can’t – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/macrogenics-plops-down-580m-for-adc-tech-domainex-nonprofit-team-up-on-parkinsons-program/">MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson’s program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyos-adc-enhertu-blows-away-roches-kadcyla-in-second-line-advanced-breast-cancer/">AstraZeneca, Daiichi Sankyo’s ADC Enhertu blows away Roche’s Kadcyla in second-line advanced breast cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/daiichi-sankyo-shuts-down-plexxikon-subsidiary-to-streamline-enhertu-adc-development/">Daiichi Sankyo shuts down Plexxikon subsidiary to streamline Enhertu, ADC development – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/riding-an-adc-hot-streak-a-new-biotech-bets-a-megaround-that-a-better-version-of-those-therapies-isnt-a-myth/">Riding an ADC hot streak, a new biotech bets a megaround that a better version of those therapies isn’t a myth – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genmab-axes-an-adc-development-program-after-the-data-fail-to-impress/">Genmab axes an ADC development program after the data fail to impress – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/promising-better-linker-tech-to-adc-field-araris-has-very-very-ambitious-plans-for-the-clinic/">Promising better linker tech to ADC field, Araris has ‘very, very ambitious’ plans for the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/amid-string-of-splashy-pandemic-ipos-adc-returns-for-its-millions/">Amid string of splashy pandemic IPOs, ADC returns for its millions – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/armed-antibody-player-adc-lands-a-105m-mega-round-to-back-pipeline-construction/">Armed antibody player ADC lands a $105M mega-round to back pipeline construction – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/">Bristol Myers breaks the bank on Eisai’s folate receptor ADC drug, laying out more than $3B+ for rights – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-celltrion-backed-biotech-is-developing-tunable-conjugates-to-crack-solid-tumors-and-it-has-eyes-on-the-clinic/">A Celltrion-backed biotech is developing ‘tunable’ conjugates to crack solid tumors — and it has eyes on the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-adc-gets-a-speedy-fda-review-for-their-dlbcl-therapy-qiagen-teams-with-the-worlds-new-favorite-biotech/">News briefing: ADC gets a speedy FDA review for their DLBCL therapy; Qiagen teams with the world’s new favorite biotech – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/padcev-gets-a-shot-at-another-indication-for-invasive-bladder-cancer-thanks-to-initial-data-readout/">Padcev gets a shot at another indication — for invasive bladder cancer — thanks to initial data readout – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/researchers-spotlight-a-basket-of-good-response-rates-for-the-next-adc-in-seattle-genetics-pipeline/">Researchers spotlight a basket of ‘good’ response rates for the next ADC in Seattle Genetics’ pipeline – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-clears-a-big-hurdle-toward-its-first-bla-as-pivotal-phii-delivers-upbeat-orr-results/">ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-rolls-the-dice-with-2-adc-deals-tied-to-35m-cash-upfronts-a-rare-antibiotic-win-for-prominently-backed-spero/">News briefing: Exelixis rolls the dice with 2 ADC deals tied to $35M cash upfronts; A rare antibiotic win for prominently-backed Spero – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/chmp-recommends-ok-for-alnylams-patisiran-amgen-scraps-a-bcma-adc/">CHMP recommends OK for Alnylam’s patisiran; Amgen scraps a BCMA ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-steams-back-to-virtual-wall-street-and-this-time-the-team-scores-a-233m-ipo-haul/">ADC steams back to virtual Wall Street — and this time the team scores a $233M IPO haul – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/boehringer-ingelheim-buys-out-next-gen-adc-player-nbe-therapeutics-in-a-deal-worth-up-to-1-4b/">Boehringer Ingelheim buys out next-gen ADC player NBE-Therapeutics in a deal worth up to $1.4B+ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-astellas-partnered-adc-nails-confirmatory-phiii-in-urothelial-cancer/">Seattle Genetics’ Astellas-partnered ADC nails confirmatory PhIII in urothelial cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/">AstraZeneca mines another $6B ADC from Daiichi Sankyo, with blockbuster ambitions to ‘redefine treatment standards’ – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fda-pushes-back-ascendis-pdufa-for-long-acting-hormone-therapy-debiopharm-takes-home-a-win-in-mid-stage-test-for-adc/">FDA pushes back Ascendis’ PDUFA for long-acting hormone therapy; Debiopharm takes home a win in mid-stage test for ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-isnt-going-public-in-the-us-after-all-while-three-other-biotech-ipos-bring-in-319m/">ADC Therapeutics isn’t going public in the US after all, while three other biotech IPOs bring in $319M – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/merck-allied-seattle-genetics-positive-update-on-its-2nd-adc-may-point-to-an-accelerated-dash-to-the-fda-finish-line/">Merck-allied Seattle Genetics’ positive update on its 2nd ADC may point to an accelerated dash to the FDA finish line – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/revenue-shrinking-sanofi-sweeps-a-phii-cancer-adc-and-tb-vaccine-program-out-of-the-pipeline-in-q2-cleanup/">Revenue shrinking, Sanofi sweeps a PhII cancer ADC and TB vaccine program out of the pipeline in Q2 cleanup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/biotheryx-collects-92m-in-series-e-round-wuxi-biologics-ups-its-stake-in-an-emerging-adc-player/">BioTheryX collects $92M in Series E round; WuXi Biologics ups its stake in an emerging ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-upsizes-ipo-offering-in-search-of-a-175m-plus-haul-novo-presents-encouraging-glp-1-data-from-obesity-study/">ADC upsizes IPO offering in search of a $175M-plus haul; Novo presents encouraging GLP-1 data from obesity study – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/three-biotechs-hunt-336m-plus-in-a-new-round-of-ipos-while-dermavant-pulls-back/">Three biotechs hunt $336M-plus in a new round of IPOs — while Dermavant pulls back – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/asco21-gileads-trodelvy-reads-out-new-subgroup-data-showing-benefit-in-earlier-line-tnbc-patients/">#ASCO21: Gilead’s Trodelvy reads out new subgroup data showing benefit in earlier-line TNBC patients – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/takeda-deserts-mersana-and-days-later-the-biotech-abandons-its-lead-drug/">Deserted by Takeda, Mersana abandons lead drug – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/gilead-and-novo-nordisk-expand-nash-deal-with-new-study-pfizer-out-licenses-adcs-to-a-biotech-startup/">Gilead and Novo Nordisk expand NASH deal with new study; Pfizer out-licenses ADCs to a biotech startup – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/2021s-nda-list-includes-some-extraordinary-accomplishments-hitting-a-new-record-on-approvals-was-just-one/">2021’s NDA list includes some extraordinary accomplishments in year #2 of the pandemic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/mercks-roger-perlmutter-steps-up-with-a-cash-heavy-4-5-billion-deal-to-ally-with-seattle-genetics-on-an-under-the-radar-adc-and-newly-approved-tukysa/">Merck’s Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/singular-focus-on-ror1-earns-velosbio-137m-to-fund-phi-adc-and-other-programs/">Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-bet-on-daiichi-sankyos-antibody-drug-conjugate-pays-off-with-pivotal-data-to-back-their-regulatory-pitches/">AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-gets-25m-upfront-for-adc-therapy-miragen-adds-european-orphan-drug-designation-pierre-fabre-buys-some-preclinical-immunotherapies/">ImmunoGen gets $25M upfront for ADC therapy; miRagen adds European orphan drug designation; Pierre Fabre buys some preclinical immunotherapies – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/can-the-antibody-drug-conjugate-model-work-for-nk-cells-acepodia-loads-up-with-another-109m-to-find-out/">Can the antibody-drug conjugate model work for NK cells? Acepodia loads up with another $109M to find out – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/what-do-the-top-10-biotech-ma-deals-of-2020-tell-us-premiums-are-in-bolt-ons-rule-and-the-adc-comeback-is-on/">What do the top 10 biotech M&A deals of 2020 tell us? Premiums are in, bolt-ons rule and the ADC comeback is on – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/preclinical-study-finds-genmab-may-hold-the-key-to-a-next-gen-triple-followup-to-mek-braf-combos/">Preclinical study finds Genmab may hold the key to a next-gen triple followup to MEK/BRAF combos – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/bolt-biotherapeutics-nabs-93-5m-to-push-provenge-inventors-new-idea-deeper-in-the-clinic/">Bolt Biotherapeutics nabs $93.5M to push Provenge inventor’s new idea deeper in the clinic – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/after-a-long-march-with-cabo-exelixis-is-expanding-its-focus-with-an-antibody-drug-conjugate-deal/">After a long march with Cabo, Exelixis is expanding its focus with an antibody-drug conjugate deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Seattle</h3></div>
          <div class="col-9">
            <p>Kottle joined Gilead in 2013, overlapping with Bischofberger’s 28-year run with the California pharma, and was VP of corporate communications after a career in media where she was a reporter for the San Francisco Chronicle , Bloomberg and the Seattle Post-Intelligencer . Kronos got in on the 2020 IPO craze last fall, topping $250 million in an upsized offering.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/silverback-therapeutics-gets-78m-boost-to-reconceptualize-antibody-drug-conjugates/">Silverback Therapeutics gets $78M boost to ‘reconceptualize’ antibody-drug conjugates – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/genentech-inks-359m-deal-with-kineta-celldex-battered-after-adc-flops-in-phiib/">Genentech inks $359M deal with Kineta; Celldex battered after ADC flops in PhIIb – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/key-bladder-cancer-data-pave-way-for-seattle-genetics-to-submit-marketing-application-for-astellas-partnered-armed-antibody/">Key bladder cancer data pave way for Seattle Genetics to submit marketing application for armed antibody – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ASCO</h3></div>
          <div class="col-9">
            <p>Now, at ASCO, the British pharma and their Japanese partner, Daiichi Sankyo, have shown off the data that led to the gastric cancer designation, which they’ll take back to the FDA. In a pivotal, 187-person Phase II trial, Enhertu shrunk tumors in 42.9% of third-line patients with HER2-positive stomach cancer, compared with 12.5% in a control arm where doctors prescribed their choice of therapy.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/">AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazeneca-daiichi-sankyo-uncork-new-tnbc-data-for-2nd-partnered-adc-and-its-adding-more-heat-under-gileads-trodelvy/">AstraZeneca, Daiichi Sankyo uncork new TNBC data for 2nd partnered ADC — and it’s adding more heat under Gilead’s Trodelvy – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/wclc-astrazeneca-builds-case-for-growing-adc-pipeline-with-double-wins-in-advanced-lung-cancer/">WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seattle-genetics-gets-ready-to-launch-its-second-adc-after-scoring-bladder-cancer-ok-with-partner-astellas/">Seattle Genetics gets ready to launch its second ADC after scoring bladder cancer OK with partner Astellas – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Japan</h3></div>
          <div class="col-9">
            <p>The first AM-Pharma executive to be based in the US, the Novo Nordisk and Alexion vet joins the company from Columbia Care  just a week after Kyowa Kirin paid the biotech more than $23 million upfront for development and commercialization rights in Japan on kidney drug ilofotase alfa .   Timothy Kieffer  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-eli-lillys-backing-a-team-of-seagen-veterans-with-adc-chops-is-looking-to-crash-the-chinese-oncology-party/">With Eli Lilly’s backing, a team of Seagen veterans with ADC chops is looking to crash the Chinese oncology party – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/jazz-pharmaceuticals-pushes-to-expand-label-on-xywav-fda-eyes-october-for-decision-on-seagens-latest-adc/">Jazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen’s latest ADC – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/news-briefing-exelixis-pays-20m-to-in-license-a-preclinical-adc-for-the-pipeline-another-preclinical-biotech-shoots-for-a-big-ipo/">News briefing: Exelixis pays $20M to in-license a preclinical ADC for the pipeline; Another preclinical biotech shoots for a big IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/fritz-gerber-who-led-roche-for-2-decades-dies-adc-therapeutics-tries-again-for-an-ipo-sets-terms/">Fritz Gerber, who led Roche for 2 decades, dies; ADC Therapeutics tries again for an IPO, sets terms – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-bet-6b-on-the-idea-now-versant-venbio-have-45m-to-birth-a-platform-play-for-radiopharmaceuticals/">Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>GlaxoSmithKline</h3></div>
          <div class="col-9">
            <p>Founded a decade ago by GlaxoSmithKline’s head of discovery chemistry, Matt Clark , X-Chem was bought out last year for an undisclosed sum by the British firm GHO Capital.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/james-sabry-adds-another-weapon-to-roche-genentech-arsenal-daiichi-sankyo-adds-adc-6/">James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6 – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/hoping-to-challenge-blockbuster-breast-cancer-franchises-a-small-dutch-biotech-says-its-adc-passed-a-phiii-test/">Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/with-decision-looming-on-jj-legends-car-t-analyst-sees-a-new-champion-emerging-in-booming-bcma-space/">With decision looming on J&J, Legend’s CAR-T, analyst sees a new champion emerging in booming BCMA space – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/">#ESMO20: Seattle Genetics eyes 4th approval with new data in a crowded field – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>ADC Bio</h3></div>
          <div class="col-9">
            <p>Manufacturing   CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work      Josh Sullivan  Associate Editor       Sterling Pharma Solutions has announced the acquisition of ADC Bio, a UK-based company that specializes in antibody drug conjugates.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/cdmo-sterling-acquires-adc-bio-ramping-up-capacity-for-antibody-drug-conjugate-manufacturing-work/">CDMO Sterling acquires ADC Bio, ramping up capacity for antibody-drug conjugate manufacturing work – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sterling-builds-up-its-api-capacity-with-big-buy-of-novartis-campus-in-ireland/">Sterling builds up its API capacity with big buy of Novartis campus in Ireland – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>VC</h3></div>
          <div class="col-9">
            <p>the VC's largest yet      Paul Schloesser  Associate Editor      French VC Kurma has been investing into several companies recently, such as ARMGO Pharma and Emergence Therapeutics. With its new biotech and healthtech-focused fund, the VC is now looking to expand its offerings in possibly its biggest fund to date.   </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/kurma-scores-175m-in-first-closing-of-biotech-healthtech-fund-the-vcs-largest-yet/">Kurma scores $175M in first closing of biotech/healthtech fund — the VC’s largest yet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/going-to-china-adc-therapeutics-spotlights-a-new-way-to-do-it-with-hillhouse-backed-overland/">Going to China? ADC Therapeutics spotlights a new way to do it with Hillhouse-backed Overland – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Shire</h3></div>
          <div class="col-9">
            <p>Once in charge of the US internal medicine and oncology franchises at Shire , Hackman leaves his post as president of US operations with EUSA Pharma . Based in Woburn, MA, ReForm Biologics focuses on what they describe as “gentler medicines” for children and the elderly.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/flagship-keeps-ex-fda-commish-stephen-hahn-busy-with-another-cmo-gig-daphne-koller-makes-key-hire-at-insitro-by-welcoming-google-and-facebook-vet/">Flagship keeps ex-FDA commish Stephen Hahn busy with another CMO gig; Daphne Koller makes key hire at insitro by welcoming Google and Facebook vet – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/a-pfizer-partner-welcomes-ex-adc-therapeutics-cmo-jay-feingold-to-the-team-amid-tough-sledding-immunovant-chooses-eli-lilly-alum-as-cfo/">A Pfizer partner welcomes ex-ADC Therapeutics CMO Jay Feingold to the team; Amid tough sledding, Immunovant chooses Eli Lilly alum as CFO – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Copenhagen</h3></div>
          <div class="col-9">
            <p>The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player      Kyle Blankenship      With the biotech boom in the US in full swing, more money than ever is flowing into the industry — but that gusher hasn’t fully translated across the pond. Now, a Danish biotech with some big-name backers has scored a record-high early fundraising round.</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/the-biotech-craze-hits-the-nordics-driving-a-record-high-62m-series-a-for-a-copenhagen-based-adc-player/">The biotech craze hits the Nordics, driving a record-high $62M Series A for a Copenhagen-based ADC player – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/seven-years-in-the-making-seattle-genetics-picks-up-early-option-on-genmabs-adc-effort/">Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Freenome</h3></div>
          <div class="col-9">
            <p>09:42 AM EDT  News Briefing   ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes</p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/adc-therapeutics-signs-pact-with-freenome-shanghai-henlius-biotech-eyes-600m-for-hong-kong-ipo/">ADC Therapeutics signs pact with Freenome; Shanghai Henlius Biotech eyes $600M for Hong Kong IPO – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/eli-lilly-dishes-out-first-milestone-payment-for-alzheimers-deal-adc-therapeutics-viela-bio-set-terms-for-ipo/">Eli Lilly dishes out first milestone payment for Alzheimer’s deal; ADC Therapeutics, Viela Bio set terms for IPO – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>BTD</h3></div>
          <div class="col-9">
            <p>AstraZeneca's Enhertu gets BTD for breast cancer; Centessa nabs $300M loan       Paul Schloesser  Associate Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/astrazenecas-enhertu-gets-btd-for-breast-cancer-centessa-nabs-300m-facility-loan/">AstraZeneca’s Enhertu gets BTD for breast cancer; Centessa nabs $300M loan – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/novartis-sets-the-tone-for-the-radiopharma-push-with-a-prized-acquisition-winning-breakthrough-therapy-designation/">Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>mirvetuximab</h3></div>
          <div class="col-9">
            <p>ImmunoGen’s drug, called mirvetuximab soravtansine, shrank tumors in 32.4% of patients at a median follow-up of 8.1 months. And five of those patients achieved a complete response.  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/immunogen-touts-a-phiii-comeback-in-ovarian-cancer-eyeing-a-2022-accelerated-approval/">ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/sanofi-beefs-up-cancer-drug-pipeline-paying-cash-hungry-immunogen-30m-for-full-rights-to-oncology-portfolio/">Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Aktis</h3></div>
          <div class="col-9">
            <p>LOG IN                Matthew Roden, Aktis Oncology CEO (MPM Capital)          March 18, 2021 07:07 AM EDT Updated 07:37 AM  </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>3 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/are-radiopharmaceuticals-ready-for-the-mainstream-novartis-bristol-myers-squibb-bet-yes-on-mpms-platform-take/">Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform take – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>2 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/radiopharma-remains-hot-as-germanys-itm-raises-109m-to-advance-neuroendocrine-cancer-program/">Radiopharma remains hot as Germany’s ITM raises $109M to advance neuroendocrine cancer program – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
          <div class="row border-bottom mb-4">
          <div class="col-3"><h3>Taiwan</h3></div>
          <div class="col-9">
            <p>Taiwan's Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells       Max Gelman  Editor      </p>
            <table class="element table table-sm table-borderless text-muted mb-0" data-config='{ "type": "table", "limit": 1, "more": "↓ show more", "less": "↑ less", "number": true }'>
              <tbody>
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>4 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/taiwans-acepodia-closes-series-b-with-the-promise-of-conjugating-antibodies-and-off-the-shelf-nk-cells/">Taiwan’s Acepodia closes Series B with the promise of conjugating antibodies and off-the-shelf NK cells – Endpoints News</a></td>
                </tr>
    
                <tr>
                  <th scope="row">1900-01-01</th>
                  <td>1 mentions</td>
                  <td><a class="result-link" href="https://endpts.com/regulus-dumps-first-gen-adpkd-treatment-in-favor-of-second-iteration-sutro-joins-bionova-in-200m-deal/">Regulus dumps first-gen ADPKD treatment in favor of second iteration; Sutro joins BioNova in $200M deal – Endpoints News</a></td>
                </tr>
    
              </tbody>
            </table>
          </div>
        </div>
  
        </div><!-- Outer col -->
    </div><!-- Container -->
    <!-- Option 1: Bootstrap Bundle with Popper -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.1.3/dist/js/bootstrap.bundle.min.js" integrity="sha384-ka7Sk0Gln4gmtz2MlQnikT1wXgYsOg+OMhuP+IlRH9sENBO0LRn5q+8nbTov4+1p" crossorigin="anonymous"></script>
  </body>
</html>
  